Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria
Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)
DOI: 10.1128/aac.00044-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von Xueyong Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Polymyxin B, Anti-Bacterial Agents, Gram-Negative Bacteria, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian Province, Natural Science Foundation of Fujian Province (Fujian Natural Science Foundation), Fujian Guiding Project of Sceince and Technology.
Abstract (Originalsprache)
Polymyxin B (PMB) remains a last-line therapeutic agent for multidrug-resistant gram-negative bacteria (MDR-GNB) infections. However, reliable pharmacokinetic (PK) data to guide nebulized PMB dosing regimens in critically ill patients are limited. This study aimed to establish a population pharmacokinetic (PopPK) model for PMB in both epithelial lining fluid (ELF) and plasma of critically ill patients with MDR-GNB pneumonia and to optimize dosing regimens. A prospective PK study was conducted in 76 adult patients receiving nebulized PMB either as monotherapy or in combination with intravenous administration. PK data were analyzed using non-linear mixed-effect modeling, with PMB concentration–time profiles described by a coupled model integrating separate two-compartment models for plasma and ELF. The final model identified albumin levels and age as significant covariates influencing PK variability. Monte Carlo simulations demonstrated that nebulization therapy either alone or combined with intravenous administration significantly enhances ELF concentration and the probability of target attainment. Additionally, Pseudomonas aeruginosa requires higher nebulized doses than Klebsiella pneumoniae and Acinetobacter baumannii . This study develops a PopPK model of PMB in ELF and plasma, providing critical insights to optimize PMB treatment strategies for patients with MDR-GNB pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Department of Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
ORCID-Profile: Xueyong Li, Hongqiang Qiu, Yu Cheng
Förderung
- Joint Funds for the Innovation of Science and Technology, Fujian Province
- Natural Science Foundation of Fujian Province (Fujian Natural Science Foundation)
- Fujian Guiding Project of Sceince and Technology
- Fujian Science and Technology Plan Social Development Guidance Project
- Funding for Top Hospital and Specialty Excellence, Fujian Province
Zitieren
APA
Li, X., Zhou, L., Wang, D., Wu, Q., Huang, X., Zhang, H., Wu, W., Liu, M., Wu, X., Qiu, H., & Cheng, Y. (2025). Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria. Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.00044-25
Vancouver
Li X, Zhou L, Wang D, Wu Q, Huang X, Zhang H, et al. Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria. Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.00044-25
BibTeX
@article{Li2025,
author = {Li, Xueyong and Zhou, Lili and Wang, Danjie and Wu, Qiong and Huang, Xuanxi and Zhang, Hui and Wu, Wenwei and Liu, Maobai and Wu, Xuemei and Qiu, Hongqiang and Cheng, Yu},
title = {Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {5},
doi = {10.1128/aac.00044-25}
}
EUVIMED